The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Disease-Free Survival

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Disease-Free Survival


Psychiatry related information on Disease-Free Survival


High impact information on Disease-Free Survival


Chemical compound and disease context of Disease-Free Survival


Biological context of Disease-Free Survival


Anatomical context of Disease-Free Survival


Associations of Disease-Free Survival with chemical compounds

  • In this trial (median follow-up, greater than 6 years) the outcomes for the two treatment groups were similar with respect to five-year disease-free survival (80 percent in both groups) and overall survival (81 percent with melphalan vs. 78 percent with 32P; P = 0.48) [2].
  • The presence of either estrogen receptors or progesterone receptors was positively correlated with disease-free survival when analyzed separately, whether or not the adjuvant regimen included an endocrine component [26].
  • As compared with the 300 patients receiving leuprolide and placebo, the 303 patients randomly assigned to receive leuprolide and flutamide had a longer progression-free survival (16.5 vs. 13.9 months; P = 0.039) and an increase in the median length of survival (35.6 vs. 28.3 months; P = 0.035) [27].
  • The presence of estrogen receptors in breast cancers is now accepted as a predictor of extended disease-free survival, but the relative value of progesterone receptors for this purpose has not been established [26].
  • At seven months, event-free survival was 67.3 percent in the group receiving heparin, 63.5 percent in the group receiving intravenous hirudin, and 68.0 percent in the group receiving both intravenous and subcutaneous hirudin (P = 0.61) [28].

Gene context of Disease-Free Survival

  • High levels of MRP expression were strongly associated with reductions in both survival and event-free survival (P < 0.001) in the overall study population and in subgroups of patients without N-myc amplification and patients with localized disease [29].
  • In parallel, data obtained in a primary breast cancer clinical series showed that disease-free survival was shorter in individuals bearing the CCR5Delta32 allele than in CCR5 wild-type patients, but only for those whose tumors expressed wild-type p53 [30].
  • FINDINGS: Disease-free survival for BRCA1 and sporadic patients at 5 years was 49% (95% CI 33-64) and 51% (43-59), respectively (p=0.98) [31].
  • Patients with a high mutant/wt ratio (ie, greater than 0.78) had significantly shorter overall and disease-free survival, whereas survival in patients with ratios below 0.78 did not differ from those without FLT3 aberrations [32].
  • Importantly, ETV6 rearrangement was associated with a favorable prognosis (5-year event-free survival: 89% +/- 6% v 60% +/- 1%, P < .01) [33].

Analytical, diagnostic and therapeutic context of Disease-Free Survival


  1. Adjuvant therapy for colon cancer. Macdonald, J.S. CA: a cancer journal for clinicians. (1997) [Pubmed]
  2. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. Young, R.C., Walton, L.A., Ellenberg, S.S., Homesley, H.D., Wilbanks, G.D., Decker, D.G., Miller, A., Park, R., Major, F. N. Engl. J. Med. (1990) [Pubmed]
  3. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. Saltz, L.B., Cox, J.V., Blanke, C., Rosen, L.S., Fehrenbacher, L., Moore, M.J., Maroun, J.A., Ackland, S.P., Locker, P.K., Pirotta, N., Elfring, G.L., Miller, L.L. N. Engl. J. Med. (2000) [Pubmed]
  4. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. Solal-Celigny, P., Lepage, E., Brousse, N., Reyes, F., Haioun, C., Leporrier, M., Peuchmaur, M., Bosly, A., Parlier, Y., Brice, P. N. Engl. J. Med. (1993) [Pubmed]
  5. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. Cassileth, P.A., Harrington, D.P., Appelbaum, F.R., Lazarus, H.M., Rowe, J.M., Paietta, E., Willman, C., Hurd, D.D., Bennett, J.M., Blume, K.G., Head, D.R., Wiernik, P.H. N. Engl. J. Med. (1998) [Pubmed]
  6. Estrogen replacement in surgical stage I and II endometrial cancer survivors. Chapman, J.A., DiSaia, P.J., Osann, K., Roth, P.D., Gillotte, D.L., Berman, M.L. Am. J. Obstet. Gynecol. (1996) [Pubmed]
  7. Aromatase inhibitors as adjuvant therapy for postmenopausal patients with early stage breast cancer. Kudachadkar, R., O'Regan, R.M. CA: a cancer journal for clinicians. (2005) [Pubmed]
  8. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. Rai, K.R., Peterson, B.L., Appelbaum, F.R., Kolitz, J., Elias, L., Shepherd, L., Hines, J., Threatte, G.A., Larson, R.A., Cheson, B.D., Schiffer, C.A. N. Engl. J. Med. (2000) [Pubmed]
  9. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. Rose, P.G., Bundy, B.N., Watkins, E.B., Thigpen, J.T., Deppe, G., Maiman, M.A., Clarke-Pearson, D.L., Insalaco, S. N. Engl. J. Med. (1999) [Pubmed]
  10. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. Matthay, K.K., Villablanca, J.G., Seeger, R.C., Stram, D.O., Harris, R.E., Ramsay, N.K., Swift, P., Shimada, H., Black, C.T., Brodeur, G.M., Gerbing, R.B., Reynolds, C.P. N. Engl. J. Med. (1999) [Pubmed]
  11. Effect of completeness of revascularization on long-term outcome of patients with three-vessel disease undergoing coronary artery bypass surgery. A report from the Coronary Artery Surgery Study (CASS) Registry. Bell, M.R., Gersh, B.J., Schaff, H.V., Holmes, D.R., Fisher, L.D., Alderman, E.L., Myers, W.O., Parsons, L.S., Reeder, G.S. Circulation (1992) [Pubmed]
  12. Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Zheng, P.Z., Wang, K.K., Zhang, Q.Y., Huang, Q.H., Du, Y.Z., Zhang, Q.H., Xiao, D.K., Shen, S.H., Imbeaud, S., Eveno, E., Zhao, C.J., Chen, Y.L., Fan, H.Y., Waxman, S., Auffray, C., Jin, G., Chen, S.J., Chen, Z., Zhang, J. Proc. Natl. Acad. Sci. U.S.A. (2005) [Pubmed]
  13. Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down syndrome cells: a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia. Taub, J.W., Matherly, L.H., Stout, M.L., Buck, S.A., Gurney, J.G., Ravindranath, Y. Blood (1996) [Pubmed]
  14. Tamoxifen therapy in primary breast cancer: biology, efficacy, and side effects. Love, R.R. J. Clin. Oncol. (1989) [Pubmed]
  15. Two schedules of teniposide with or without cisplatin in advanced non-small-cell lung cancer: a randomized study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Splinter, T.A., Sahmoud, T., Festen, J., van Zandwijk, N., Sörenson, S., Clerico, M., Burghouts, J., Dautzenberg, B., Kho, G.S., Kirkpatrick, A., Giaccone, G. J. Clin. Oncol. (1996) [Pubmed]
  16. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. Clark, G.M., Dressler, L.G., Owens, M.A., Pounds, G., Oldaker, T., McGuire, W.L. N. Engl. J. Med. (1989) [Pubmed]
  17. Heat shock protein hsp70 in patients with axillary lymph node-negative breast cancer: prognostic implications. Ciocca, D.R., Clark, G.M., Tandon, A.K., Fuqua, S.A., Welch, W.J., McGuire, W.L. J. Natl. Cancer Inst. (1993) [Pubmed]
  18. Membrane-associated CD19-LYN complex is an endogenous p53-independent and Bc1-2-independent regulator of apoptosis in human B-lineage lymphoma cells. Myers, D.E., Jun, X., Waddick, K.G., Forsyth, C., Chelstrom, L.M., Gunther, R.L., Tumer, N.E., Bolen, J., Uckun, F.M. Proc. Natl. Acad. Sci. U.S.A. (1995) [Pubmed]
  19. Increased frequency of expression of elevated dihydrofolate reductase in T-cell versus B-precursor acute lymphoblastic leukemia in children. Matherly, L.H., Taub, J.W., Wong, S.C., Simpson, P.M., Ekizian, R., Buck, S., Williamson, M., Amylon, M., Pullen, J., Camitta, B., Ravindranath, Y. Blood (1997) [Pubmed]
  20. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Inoue, K., Sugiyama, H., Ogawa, H., Nakagawa, M., Yamagami, T., Miwa, H., Kita, K., Hiraoka, A., Masaoka, T., Nasu, K. Blood (1994) [Pubmed]
  21. Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. Soiffer, R.J., Murray, C., Gonin, R., Ritz, J. Blood (1994) [Pubmed]
  22. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Relling, M.V., Hancock, M.L., Boyett, J.M., Pui, C.H., Evans, W.E. Blood (1999) [Pubmed]
  23. Detection of thymidylate synthase expression in lymph node metastases of colorectal cancer can improve the prognostic information. Ohrling, K., Edler, D., Hallström, M., Ragnhammar, P., Blomgren, H. J. Clin. Oncol. (2005) [Pubmed]
  24. Automated quantitative analysis of tissue microarrays reveals an association between high Bcl-2 expression and improved outcome in melanoma. Divito, K.A., Berger, A.J., Camp, R.L., Dolled-Filhart, M., Rimm, D.L., Kluger, H.M. Cancer Res. (2004) [Pubmed]
  25. Human granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: a Children's Cancer Group Study. Heath, J.A., Steinherz, P.G., Altman, A., Sather, H., Jhanwar, S., Halpern, S., Pieters, R., Shah, N., Steinherz, L., Tannous, R., Terry, W., Trigg, M.E. J. Clin. Oncol. (2003) [Pubmed]
  26. Progesterone receptors as a prognostic factor in Stage II breast cancer. Clark, G.M., McGuire, W.L., Hubay, C.A., Pearson, O.H., Marshall, J.S. N. Engl. J. Med. (1983) [Pubmed]
  27. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. Crawford, E.D., Eisenberger, M.A., McLeod, D.G., Spaulding, J.T., Benson, R., Dorr, F.A., Blumenstein, B.A., Davis, M.A., Goodman, P.J. N. Engl. J. Med. (1989) [Pubmed]
  28. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators. Serruys, P.W., Herrman, J.P., Simon, R., Rutsch, W., Bode, C., Laarman, G.J., van Dijk, R., van den Bos, A.A., Umans, V.A., Fox, K.A. N. Engl. J. Med. (1995) [Pubmed]
  29. Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. Norris, M.D., Bordow, S.B., Marshall, G.M., Haber, P.S., Cohn, S.L., Haber, M. N. Engl. J. Med. (1996) [Pubmed]
  30. CCR5 expression influences the progression of human breast cancer in a p53-dependent manner. Mañes, S., Mira, E., Colomer, R., Montero, S., Real, L.M., Gómez-Moutón, C., Jiménez-Baranda, S., Garzón, A., Lacalle, R.A., Harshman, K., Ruíz, A., Martínez-A, C. J. Exp. Med. (2003) [Pubmed]
  31. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Verhoog, L.C., Brekelmans, C.T., Seynaeve, C., van den Bosch, L.M., Dahmen, G., van Geel, A.N., Tilanus-Linthorst, M.M., Bartels, C.C., Wagner, A., van den Ouweland, A., Devilee, P., Meijers-Heijboer, E.J., Klijn, J.G. Lancet (1998) [Pubmed]
  32. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Thiede, C., Steudel, C., Mohr, B., Schaich, M., Schäkel, U., Platzbecker, U., Wermke, M., Bornhäuser, M., Ritter, M., Neubauer, A., Ehninger, G., Illmer, T. Blood (2002) [Pubmed]
  33. 12p abnormalities and the TEL gene (ETV6) in childhood acute lymphoblastic leukemia. Raimondi, S.C., Shurtleff, S.A., Downing, J.R., Rubnitz, J., Mathew, S., Hancock, M., Pui, C.H., Rivera, G.K., Grosveld, G.C., Behm, F.G. Blood (1997) [Pubmed]
  34. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. Allred, D.C., Clark, G.M., Elledge, R., Fuqua, S.A., Brown, R.W., Chamness, G.C., Osborne, C.K., McGuire, W.L. J. Natl. Cancer Inst. (1993) [Pubmed]
  35. Dipyridamole-induced ischemia as a prognostic marker of future adverse cardiac events in adult patients with hypertrophic cardiomyopathy. Echo Persantine Italian Cooperative (EPIC) Study Group, Subproject Hypertrophic Cardiomyopathy. Lazzeroni, E., Picano, E., Morozzi, L., Maurizio, A.R., Palma, G., Ceriati, R., Iori, E., Barilli, A. Circulation (1997) [Pubmed]
  36. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Kaspers, G.J., Veerman, A.J., Pieters, R., Van Zantwijk, C.H., Smets, L.A., Van Wering, E.R., Van Der Does-Van Den Berg, A. Blood (1997) [Pubmed]
  37. Concomitant granulocyte colony-stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia: a randomized phase III trial. Ottmann, O.G., Hoelzer, D., Gracien, E., Ganser, A., Kelly, K., Reutzel, R., Lipp, T., Busch, F.W., Schwonzen, M., Heil, G. Blood (1995) [Pubmed]
WikiGenes - Universities